Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by James Chan
Best’s Commentary: Proposed Risk-Based Capital Change in Hong Kong Could Bolster Market’s Global Standing Original
Best’s Commentary: Proposed Risk-Based Capital Change in Hong Kong Could Bolster Market’s Global Standing HONG KONG--(BUSINESS WIRE)--Proposed changes in how the Hong Kong Insurance Authority (HKIA) evaluates non-life insurers’ required capital levels around natural catastrophes and man-made risks, as well as offshore reinsurance business, could bolster this geographic market’s position as a global reinsurance and risk management hub, according to a new AM Best report.
A humanized engineered heart tissue platform for cardiotoxicity assessment
|
ArticleOnline now102856Open access Affiliations & Notes 1Division of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA 2Department of Radiation Oncology, University of California, Davis, Sacramento, CA 95817, USA 3Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA 95616, USA 4Department of Neurobiology, Physiology, and Behavior, University of...
By Hillary K.J. Kao, Padmini Sirish, Christophe Morisseau, Rasheed Sule, Ming-Fo Hsu, James Overton, Valeriy Timofeyev, Alexander A. Merleev, Gabriela Grigorean, Brett S Phinney, Emanual Maverakis, Aldrin Gomes, Fawaz Haj, Jan Nolta, James Chan, Bruce D. Hammock, Deborah K. Lieu, Nipavan Chiamvimonvat, Yao-Hui Sun, Daphne A. Diloretto, Regan L. Smithers
|
Stem Cell Reports
Verified
AM Best Affirms Credit Ratings of China Reinsurance (Group) Corporation and Its Subsidiaries
AM Best Affirms Credit Ratings of China Reinsurance (Group) Corporation and Its Subsidiaries HONG KONG--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a+” (Excellent) of China Reinsurance (Group) Corporation (China Re) (China) and its subsidiaries. The outlook of these Credit Ratings (ratings) is stable.
AM Best Affirms Credit Ratings of Central Reinsurance Corporation Original
HONG KONG--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of “a” (Excellent) of Central Reinsurance Corporation (Central Re) (Taiwan). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Central Re’s balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, favourable business profile and appropriate enterprise risk management.
Fraud detection empowered by federated learning with the Flower framework on Amazon SageMaker AI | Amazon Web Services
Fraud detection remains a significant challenge in the financial industry, requiring advanced machine learning (ML) techniques to detect fraudulent patterns while maintaining compliance with strict privacy regulations. Traditional ML models often rely on centralized data aggregation, which raises concerns about data security and regulatory constraints.
Best’s Market Segment Report: Taiwan’s Non-Life Insurance Premiums Continue to Increase Amid Underwriting Improvements Original
HONG KONG--(BUSINESS WIRE)--Taiwan’s domestic non-life insurance premium continued to increase in 2024, growing 10.5% to reach TWD 278.5 billion (USD 9.2 billion), according to a new AM Best report. The Best’s Market Segment Report, “Taiwan Non-Life Segment’s Operating Performance Supported by Tighter Underwriting Guidelines,” also notes that this segment’s overall capital & surplus level has continued to improve and crossed the TWD 150 billion mark last year.
Atrasentan Tablets (Vanrafia)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD The U.S. Food and Drug Administration (FDA) has approved atrasentan, the first selective endothelin A receptor (ETAR) antagonist to reduce proteinuria in adults with immunoglobulin A nephropathy. It was approved under accelerated approval based on surrogate outcome.
Best’s Commentary: Taiwan Dollar Rallies; Life Insurers More Exposed to Foreign Exchange Risk Original
HONG KONG--(BUSINESS WIRE)--The Taiwan dollar has rallied against the U.S. dollar at an unprecedented pace over the past few days, which holds implications for domestic life insurers that have been allocating a large portion of their invested assets in foreign investments, mainly USD-denominated fixed income securities, according to an AM Best commentary.
Gepotidacin Tablets (Blujepa)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD The U.S. Food and Drug Administration (FDA) has approved gepotidacin, a first-in-class antibacterial medication for the treatment of uncomplicated urinary tract infections (uUTIs). Gepotidacin is an oral triazaacenaphthylene antibiotic that inhibits two essential enzymes in bacterial deoxyribonucleic acid (DNA) replication. It will be distributed by GlaxoSmithKline as Blujepa.
Lymph Node Yield and Colorectal Cancer Survival: A Bowel Cancer Outcomes Registry Cohort Study
Corresponding Author Bruce D. Wilkie Department of Surgery, Eastern Health, Box Hill, Victoria, Australia Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Parkville, Victoria, Australia Department of General Surgery, Austin Health, Heidelberg, Victoria, Australia Correspondence: Bruce D.
Non‐Invasive Depth Profiling of Base Cosmetic Formulations in the Skin Using Handheld Confocal Raman Spectroscopy
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description jbio202400423-sup-0001-TableS1.docxWord 2007 document , 16.9 KB Table S1. Optimized MRM transitions and compound-dependent parameters for UPLC-MS/MS analysis of ceramides and their corresponding internal standards. References 1, , , and , “Skin, Reactive Oxygen Species, and Circadian Clocks,” Antioxidants & Redox Signaling 20 (2014), https://doi.org/10.1089/ars.2013.5645.
"Researching COVID to Enhance Recovery (RECOVER) Pediatric Study Protoc" by Rachel S Gross, Tanayott Thaweethai et al.
IMPORTANCE: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or "Long COVID") in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in children and young adults. OBSERVATIONS: We describe the protocol for the Pediatric Observational Cohort Study of the NIH's REsearching COVID to Enhance Recovery (RECOVER) Initiative.
π **Seeking a US-Based Developer (or Anyone Interested) for a Profitable Collaboration** π°
Hello, Are you looking for an easy way to generate extra income? Whether youβre a developer struggling to find projects, someone with a tech background but not in coding, or just someone open to passive income, this might be perfect for you! β
You let me use your Upwork or LinkedIn profile to secure high-paying projects. β
If you have a tech background, you can also participate in meetings, but itβs optional.
How Clinical Study Software Transforms Data Management
Clinical research used to be complicated, with teams drowning in paperwork and struggling to track data. Now, various software solutions enable researchers to catch safety issues faster, make informed decisions about their study’s progress, and produce reliable results that could influence future medical practices. At its core, good data management is critical.
InnerSelf's Daily Inspiration: October 23, 2024
Image by James Chan This is Marie T. Russell, co-publisher of InnerSelf.com, wishing you a day of trusting that you are loved and protected (today and every day). Comment from Marie: One of my favorite things to tell myself (affirm) if I am having doubts or fears about something is: "I am safe. I am protected. I am well-taken care of." Or simply "I am safe" which covers all aspects of life: health, day-to-day situations, life decisions, etc.
Resmetirom Tablets (Rezdiffra)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The U.S. Food and Drug Administration (FDA) has approved the first drug and first-in-class for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis [NASH]).
Guest column: Don't forget about environmental costs of switch to e-vehicles
Skip to Content Advertisement 1 • • You can save this article by registering for free here. Or sign-in if you have an account. Article content By: James Chan and Melissa O’Rourke In pursuit of net-zero emissions by 2050 — or what it describes as “clean air and good jobs” — Canada has committed more than $30 billion towards a nationwide transition to electric vehicles (EVs).
Our Inner Donald Trump and Inner Jesus
Once again, we have arrived at the season of Lent, the time when the Church calls us to reflect on our lives and to reform those corners of the soul where we have a need. It is the time of preparation for celebrating the great feast of Easter, the resurrection to new life by Jesus the Christ and for ourselves. Given the political and moral situation in my country, the United States, I have thought of a different way to approach this annual task that we never like to do.
Nuestros Donald Trump interior y Jesús interior
Una vez más, hemos llegado al tiempo de la Cuaresma, la época en que la Iglesia nos llama a reflexionar sobre nuestras vidas y a reformar aquellos rincones del alma donde tenemos una necesidad. Es tiempo de preparación para celebrar la gran fiesta de Pascua, la resurrección a una nueva vida por parte de Jesucristo y para nosotros mismos.
How Sault Area Hospital uses technology to improve care by engaging patients before, during, and after their stay
Many of the healthcare issues that surfaced during the pandemic have also been left behind in its wake. Everything from clinician burnout and cognitive burden, to a shortage of healthcare workers and hospital backlogs. Whether brought on by the pandemic or exacerbated by it, we simply can’t sit back and hope these problems will resolve themselves.
A Look At Lol's Impact On Competitive Gaming
Free Press Release DB | Press Release Date : Sep 10, 2023 Download Here you will find the best counters for your feared League of Legends champion In the realm of competitive gaming, few titles have left as indelible a mark as League of Legends. Over the years, LoL has played a pivotal role in shaping the landscape of esports, transforming it into a global phenomenon.
Outcomes of cataract surgery in paediatric uveitis: A multisite study
No abstract is available for this article. Open Research The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. REFERENCES 1, , , et al. Long-term outcomes of cataract surgery in children with uveitis. Indian J Ophthalmol. 2019; 67(4): 490- 495. doi:10.4103/ijo.IJO_846_18 2, , , et al. Cataract surgery with primary lens implantation in children with chronic uveitis.
Official Look At The Packer x Reebok Answer IV Ultramarine
Previewed earlier this month by James Chan, Global Senior Brand Communications Marketing Manager - Collaborations over at Reebok, today we have the full scoop on Packer’s latest collaboration with Reebok Classics. The two brands have come together on a limited edition colorway of the classic Allen Iverson silhouette, the Reebok Answer IV. Dubbed the “Ultramarine” edition, the Packer x Reebok Answer IV draws inspiration from AI’s unique demeanor and style of the late 90s/early 00s.
Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design
Abstract Importance The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or “Long COVID”) in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in children and young adults. Observations We describe the protocol for the Pediatric Observational Cohort Study of the NIH’s REsearching COVID to Enhance Recovery (RECOVER) Initiative.
Συνεχείς επιθέσεις κατά Χριστιανών από φανατικούς Εβραίους στους Αγίους Τόπους
Image by James Chan from Pixabay Του Ιωάννη Μπαλτζώη* Τον Δεκέμβριο του 2018, μιλώντας σε χριστιανοσιωνιστές στο Ρίο ντε Τζανέιρο,ο πρωθυπουργός Μπενιαμίν Νετανιάχου υποστήριξε: «Εάν είσαι Χριστιανός στη Μέση Ανατολή, υπάρχει μόνο ένα μέρος όπου είσαι ασφαλής. Υπάρχει μόνο ένα μέρος όπου η χριστιανική κοινότητα αναπτύσσεται , ευημερούσα. Αυτό είναι στο κράτος του Ισραήλ».
MAS Imposes Business Conduct Requirements for Corporate Finance Advisers, with Effect from 1 October 2023
Introduction On 23 February 2023, the Monetary Authority of Singapore ("MAS") issued a new Notice SFA-04-N21 on "Business Conduct Requirements for Corporate Finance Advisers" ("Notice"). The Notice imposes a mandatory baseline standard of conduct for corporate finance advisers (as elaborated below).
New Regulations for Filing-Based Administration of Overseas Securities Offering and Listing by Domestic Companies
Introduction On 17 February 2023, the China Securities Regulatory Commission ("CSRC") published new regulations for the filing-based administration of overseas securities offering and listing by companies that are incorporated in the People's Republic of China ("PRC") and the domestic operating entities of companies whose securities are indirectly offered and listed overseas (collectively referred to as "domestic companies").
SGX RegCo Mandates Tenure Limit on Independent Directors and Disclosure of Remuneration Details of Directors & CEOs
On 11 January 2023, Singapore Exchange Regulation ("SGX RegCo") announced that the following new requirements will apply to issuers…
Asia’s First Accredited Trainers for the SDG Impact Standards
Flagship Initiative of the United Nations Development Programme (“UNDP”). Moving the private sector from sustainability commitment, to decision and action. HONG KONG, CHINA, December 12, 2022 / EINPresswire.com/ -- PIE Strategy, a certified impact consultancy providing independent ESG advisory services to corporations in Asia, has, in November, had two of its sustainability specialists accredited by UNDP’s SDG Impact as Accredited Trainers for the SDG Impact Standards.
Madrasah Al-Kahfi Leads the Emerging Trend for Open Access Learning in South East Asia
MALAYSIA, October 24, 2022 / EINPresswire.com/ -- Madrasah Al-Kahfi, an open learning platform focused on religious, linguistic, classical Islamic teachings, and community well-being knowledge, has paved its way into the hearts of the Muslims of Malaysia and Indonesia, which sum up to almost 250 million Muslim population.
Oteseconazole Capsules (Vivjoa)
The FDA has approved the first drug to reduce recurrent vulvovaginal candidiasis (RVVC) in women. Oteseconazole is an orally active azole antifungal agent with high affinity for a key yeast cytochrome (CYP) isoenzyme (CYP51) and lower affinity for a range of human CYP isoenzymes.1 It received priority review and orphan designation. It is distributed by as Vivjoa.
Etafilcon A Drug-Eluting Contact Lens with Ketotifen (Acuvue Theravision with Ketotifen)
The FDA has approved the first drug-eluting contact lens for correcting ametropia as well as treating ocular allergic itch caused by allergic conjunctivitis. The lens contains and releases ketotifen, a H1 histamine receptor antagonist with mast cell stabilizing properties. It is distributed as Acuvue Theravision with Ketotifen.
New from Kordz | Kordz
PRO Hook and Loop Kordz Pro Hook and Loop is supplied in a 10m continuous length, allowing installers to create custom cable ties. Using Kordz soft, fluff-free Hook and Loop makes it easier than ever to dress cables for a complete Kordz ecosystem with ‘Connectivity Assured’.
Dexmedetomidine Sublingual Film (Igalmi)
The FDA has approved the first orally dissolving, self-administered sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar disorders. Dexmedetomidine is an alpha-2 adrenergic agonist originally approved in 1999 for use in ICUs in intubated and mechanically ventilated patients and procedural sedation in non-intubated adults.1 The sublingual film is distributed as Igalmi.
Donepezil Transdermal Patch (Adlarity)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved a transdermal system to treat mild, moderate, or severe Alzheimer’s disease (AD). Donepezil, an anticholinesterase (ACH) inhibitor, has been available as an oral form since 1996.
Daridorexant Tablets (Quviviq)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved a third member of the dual orexin receptor antagonist (DORA) class to treat insomnia. The orexin neuropeptide system (orexin A and orexin B) plays a role in wakefulness.1 Blocking these receptors promotes sleep.
Bebtelovimab Injection
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has issued an emergency use authorization (EUA) for a monoclonal antibody to treat COVID-19. Bebtelovimab (BEB) is a recombinant neutralizing human IgG1k monoclonal antibody to the spike protein of SARS-CoV-2.
Abrocitinib Tablets/Upadacitinib Extended-Release Tablets (Cibinqo/Rinvoq)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved two oral, selective, reversible Janus kinase-1 (JAK-1) inhibitors to treat atopic dermatitis (AD).
Clindamycin Vaginal Gel 2% (Xaciato)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved a one-course treatment for bacterial vaginosis. The product received qualified infectious disease product, fast track, and priority review designations. Clindamycin gel is distributed as Xaciato.
Sotrovimab Injection
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. In May 2021, the FDA issued an emergency use authorization (EUA) for the monoclonal antibody (mAb) sotrovimab to treat mild-to-moderate COVID-19. Sotrovimab is a recombinant human IgG1 kappa mAb that binds to the spike protein of SARS-CoV-2.
Chan resigns to contest
BY: Loop Author 09:07, January 25, 2022 1 read Ok Tedi Mining Limited (OTML) has announced the resignation of one of its directors, James Byron Chan, after serving more than three years on the OTML Board. Mr Chan who was also member of the OTML Board’s Audit and Risk Committee since his appointment on the 1st August, 2018 submitted his resignation on Sunday January 16, 2022 to contest the National General Elections in June this year.
Inclisiran Injection (Leqvio)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved the first small interfering RNA (siRNA) to lower low-density lipoprotein cholesterol (LDL-C). Inclisiran acts by inhibiting the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9).
Nirmatrelvir and Ritonavir Tablets (Paxlovid)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco.
Pilocarpine Hydrochloride Ophthalmic Solution 1.25% (Vuity)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved eye drops to treat presbyopia, commonly known as age-related blurry near vision. Presbyopia is a progressive condition that affects adults older than age 40 years.
Varenicline Nasal Spray (Tyrvaya)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved a nasal spray to treat dry eyes using the nasolacrimal reflex pathway.
Celecoxib and Tramadol Hydrochloride Tablets (Seglentis) C-IV
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved an analgesic combination of celecoxib, a selective cyclooxygenase-2 inhibitor, and tramadol, an opioid analgesic. The formulation is a co-crystal containing 1:1 molecular ratio of tramadol and celecoxib (CTC).
Atogepant Tablets (Qulipta)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved a second non-injectable calcitonin gene-related peptide (CGRP) receptor antagonist to prevent episodic migraine in adults.
Difelikefalin Injection (Korsuva)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved the first-in-class selective kappa opioid receptor (KOR) agonist for the treatment of moderate-to-severe pruritus in adults undergoing hemodialysis (i.e., uremic pruritus). Difelikefalin is a synthetic peptide marker.
Dihydroergotamine Nasal Spray (Trudhesa)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved a new intranasal formulation of dihydroergotamine mesylate (INP104) for the acute treatment of migraine headaches.
Insulin Glargine-yfgn Injection (Semglee)
By William Elliott, MD, FACP, and James Chan, PharmD, PhD Dr. Elliott is Assistant Clinical Professor of Medicine, University of California, San Francisco. Dr. Chan is Associate Clinical Professor, School of Pharmacy, University of California, San Francisco. The FDA has approved the first biosimilar and interchangeable insulin. The agency approved insulin glargine-yfgn as a biosimilar to insulin glargine (Lantus) in June 2020.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with James
Contact James, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack